 SEATTLE, April 07, 2022 GLOBE NEWSWIRE -- Neoleukin Therapeutics, Inc., Neoleukin NASDAQ:NLTX, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on Thursday, April 14, 2022 at 12:00 p.m. Eastern. 